TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04300556: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conj

Sponsor: Eisai Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 182 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT04300556 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04300556 Rescue Dossier →